Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00028314 · ClinicalTrials.gov registry record · NA

Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients

A NA study of HIV Infections and Lipodystrophy, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
NA
Development phase
150
Enrollment target
20
Study locations

NCT00028314 is a NA study of HIV Infections and Lipodystrophy that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 150 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (66% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00028314, a NA study of HIV Infections and Lipodystrophy, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
NA
Development phase
150 participants
Enrollment target
20
Study locations

Study Summary

The goals of this study are to find out if fat wasting and weight loss in the arms and legs of HIV patients taking highly active antiretroviral therapy (HAART) are caused by nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and if wasting can be reversed if the NRTI is stopped and replaced with other anti-HIV drugs.

Conditions Studied

HIV Infections Lipodystrophy Wasting Disease

Interventions

  • DRUG Nevirapine
  • DRUG Lopinavir/Ritonavir
  • DRUG Abacavir sulfate
  • DRUG Atazanavir/Ritonavir

Study Locations (20)

Illinois

  • Northwestern University CRS - Chicago
  • Rush Univ. Med. Ctr. ACTG CRS - Chicago
  • Cook County Hosp. CORE Ctr. - Chicago

Indiana

  • Indiana Univ. School of Medicine, Infectious Disease Research Clinic - Indianapolis
  • Indiana Univ. School of Medicine, Wishard Memorial - Indianapolis
  • Methodist Hosp. of Indiana - Indianapolis

Ohio

  • Univ. of Cincinnati CRS - Cincinnati
  • MetroHealth CRS - Cleveland
  • The Ohio State University Medical Center - Columbus

California

  • UCLA CARE Center CRS - Los Angeles
  • Harbor-UCLA Med. Ctr. CRS - Torrance

Massachusetts

  • Beth Israel Deaconess Med. Ctr., ACTG CRS - Boston
  • SSTAR, Family Healthcare Ctr. - Fall River

Missouri

  • St. Louis ConnectCare, Infectious Diseases Clinic - St Louis
  • Washington U CRS - St Louis

New York

  • Beth Israel Med. Ctr., ACTU - New York
  • NY Univ. HIV/AIDS CRS - New York

Colorado

  • University of Colorado Hospital CRS - Aurora

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2002-03
Est. Completion 2005-03
Phase NA

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00028314

The ClinicalTrials.gov registry entry for NCT00028314 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (66% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with HIV Infections appearing as the primary indexed condition, and to 4 interventions - of which Nevirapine is the first listed.

NCT00028314 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Illinois, Indiana, Ohio.

Frequently Asked Questions

What is clinical trial NCT00028314 about?

NCT00028314 is a clinical study titled "Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients". The goals of this study are to find out if fat wasting and weight loss in the arms and legs of HIV patients taking highly active antiretroviral therapy (HAART) are caused by nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and if wasting can be reversed if the NRTI is stopped and repla...

What is the current status of trial NCT00028314?

This trial is currently completed. It is a NA study. The enrollment target is 150 participants. The study started on 2002-03. Estimated completion is 2005-03.

What conditions does trial NCT00028314 study?

This clinical trial studies the following conditions: HIV Infections, Lipodystrophy, Wasting Disease.

What interventions are being tested in trial NCT00028314?

The interventions under investigation include: Nevirapine (DRUG), Lopinavir/Ritonavir (DRUG), Abacavir sulfate (DRUG), Atazanavir/Ritonavir (DRUG).

Who is sponsoring clinical trial NCT00028314?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00028314 being conducted?

This trial has 20 study locations across California, Colorado, Hawaii, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

Lipodystrophy

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.